Bioniz Therapeutics - Peptide Cytokine Inhibitors Patent Grant US12600757B2

The USPTO granted Patent US12600757B2 to Bioniz Therapeutics, Inc. covering stable peptide antagonists designed to inhibit γc-cytokine family activity. The patent includes 16 claims and names inventors Nicholas Doerr, Laith Q. Al-Mawsawi, and Nazli Azimi. The peptides are based on the γc-subunit binding site consensus and are capable of inhibiting multiple γc-cytokine family members.

For pharmaceutical and biotechnology companies developing cytokine-targeted therapeutics, this patent establishes intellectual property protection around peptide-based approaches for treating γc-cytokine-associated diseases including leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases, and graft-versus-host disease (GvHD). R&D programs targeting these pathways should conduct freedom-to-operate analysis to assess potential licensing or design-around needs.